Skip to main content

RUBY-4 Clinical Study

Immune Thrombocytopenia

RUBY-4 is a phase 1b/2 clinical study that is being conducted to determine if an investigational drug called povetacicept is safe and beneficial for people with ITP whose disease is not currently well controlled with standard medication(s).

All participants will receive povetacicept. Povetacicept is administered by injection under the skin.

Proud supporter of PDSA

Learn more about PDSA

Proud supporter of ITP Australia

learn more about ITP Australia

Do you have ITP?

Povetacicept is designed to reduce the inflammation and harmful antibodies that destroy platelets in ITP, which may decrease bleeding.

Investigational means that povetacicept is still being evaluated and is not approved by any health authority (e.g., the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA)).

Additional information is available at RUBY-4

Who can join RUBY-4?

  • 18 years of age or older
  • Diagnosed with ITP at least three months ago
  • Received at least two prior treatments for ITP
  • Currently have low platelet counts

Additional requirements apply. Our study doctors can help determine if you qualify.

learn more about clinical studies and povetacicept

What happens if I join the study?

Participating in the study is optional. Before joining RUBY-4, you will be told what to expect, including the study visit schedule and what might happen at each visit. You will have a chance to ask questions and time to decide if you want to take part.

If your study physician determines you are a candidate you will be given the option to join the study. The periods of the study are:


Screening (up to 28 days)

Undergo tests to confirm you qualify

Treatment Period (approximately 6 months)

Attend visits to undergo study tests and to receive povetacicept

Optional Treatment Extension Period (approximately 6 months)

If your study doctor thinks povetacicept is helping your ITP, you may continue to receive the study drug for an additional 6 months

Follow-up (8 weeks)

Attend 2 final visits

You may stop taking the study drug or leave the study at any time, and this will not affect your regular medical care.

All participants receive povetacicept provided at no cost, and reimbursement may be available for study-related expenses such as travel.